Catheter ablation of AF  safety and efficacy in DM patients is similar to general population , especially when performed in younger patients with satisfactory glycemic control .
Catheter ablation of AF reduces the amount of patients requiring AADs , an additional benefit in this population commonly exposed to adverse effects of AF pharmacological treatments
AIMS Diabetes mellitus ( DM ) and atrial fibrillation ( AF ) share pathophysiological links , as supported by the high prevalence of AF within DM patients .
Catheter ablation of AF ( AFCA ) is an established therapeutic option for rhythm control in drug resistant symptomatic patients .
Its efficacy and safety among patients with DM is based on small population s , and long-term outcome is unknown .
The present systematic review and meta- analysis aims to assess safety and long-term outcome of AFCA in DM patients , focusing on predictors of recurrence .
The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association.
AIMS The Atrial Fibrillation Ablation Pilot Study is a prospect i ve registry design ed to describe the clinical epidemiology of patients undergoing an atrial fibrillation ( AFib ) ablation  , and the diagnostic/therapeutic processes applied across Europe . The aims of the 1-year follow-up were to analyse how centres assess in routine clinical practice the success of the procedure and to evaluate the success rate and long-term safety/complications . METHODS AND RESULTS Seventy-two centres in 10 European countries were asked to enrol 20 consecutive patients undergoing a first AFib ablation procedure .  A web-based case report form captured information on pre-procedural , procedural , and 1-year follow-up data . Between October 2010 and May 2011 , 1410 patients were included and 1391 underwent an AFib ablation ( 98.7 % ) . A total of 1300 patients ( 93.5 % ) completed a follow-up control 367 ± 42 days after the procedure . Arrhythmia documentation was done by an  electrocardiogram  in 76 % ,  Holter-monitoring  in 52 % ,  transtelephonic monitoring in 8 % , and /or implanted systems in 4.5 % . Over 50 % became asymptomatic . Twenty-one per cent were re-admitted due to post-ablation arrhythmias . Success without antiarrhythmic drugs was achieved in 40.7 % of patients ( 43.7 % in paroxysmal AF ; 30.2 % in persistent AF ; 36.7 % in long-lasting persistent AF ) . A second ablation was required in 18 % of the cases and 43.4 % were under antiarrhythmic treatment . Thirty-three patients ( 2.5 % ) suffered an adverse event , 272 ( 21 % ) experienced a left atrial tachycardia , and 4 patients died ( 1 haemorrhagic stroke , 1 ventricular fibrillation in a patient with ischaemic heart disease , 1 cancer , and 1 of unknown cause ) . CONCLUSION The AFib Ablation Pilot Study provided crucial information on the epidemiology , management , and outcomes of catheter ablation of AFib in a real-world setting . The methods used to assess the success of the procedure appeared at least suboptimal . Even in this context , the 12-month success rate appears to be somewhat lower to the one reported clinical trials
Catheter ablation of AF  safety and efficacy in DM patients is similar to general population , especially when performed in younger patients with satisfactory glycemic control .
Catheter ablation of AF reduces the amount of patients requiring AADs , an additional benefit in this population commonly exposed to adverse effects of AF pharmacological treatments
AIMS Diabetes mellitus ( DM ) and atrial fibrillation ( AF ) share pathophysiological links , as supported by the high prevalence of AF within DM patients .
Catheter ablation of AF ( AFCA ) is an established therapeutic option for rhythm control in drug resistant symptomatic patients .
Its efficacy and safety among patients with DM is based on small population s , and long-term outcome is unknown .
The present systematic review and meta- analysis aims to assess safety and long-term outcome of AFCA in DM patients , focusing on predictors of recurrence .